

Supplemental Digital Content 9. Mean change from baseline in **(A)** weight and **(B)** BMI at Weeks 96 and 144 (data not collected at Week 48 visit) in the overall safety population and in **(C)** weight and **(D)** BMI at Week 144 by sex. BMI, body mass index; DTG, dolutegravir; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.

